Literature DB >> 22128259

Altered Regulation of Renal Nitric Oxide and Atrial Natriuretic Peptide Systems in Lipopolysaccharide-induced Kidney Injury.

Eun Hui Bae1, In Jin Kim, Seong Kwon Ma, Jong Un Lee, Soo Wan Kim.   

Abstract

Nitric oxide (NO) and atrial natriuretic peptide (ANP) may induce vascular relaxation by increasing the production of cyclic guanosine monophosphate (cGMP), an important mediator of vascular tone during sepsis. This study aimed to determine whether regulation of NO and the ANP system is altered in lipopolysaccharide (LPS)-induced kidney injury. LPS (10 mg.kg(-1)) was injected in the tail veins of male Sprague-Dawley rats; 12 hours later, the kidneys were removed. Protein expression of NO synthase (NOS) and neutral endopeptidase (NEP) was determined by semiquantitative immunoblotting. As an index of synthesis of NO, its stable metabolites (nitrite/nitrate, NOx) were measured using colorimetric assays. mRNA expression of the ANP system was determined by real-time polymerase chain reaction. To determine the activity of guanylyl cyclase (GC), the amount of cGMP generated in response to sodium nitroprusside (SNP) and ANP was calculated. Creatinine clearance decreased and fractional excretion of sodium increased in LPS-treated rats compared with the controls. Inducible NOS protein expression increased in LPS-treated rats, while that of endothelial NOS, neuronal NOS, and NEP remained unchanged. Additionally, urinary and plasma NOx levels increased in LPS-treated rats. SNP-stimulated GC activity remained unchanged in the glomerulus and papilla in the LPS-treated rats. mRNA expression of natriuretic peptide receptor (NPR)-C decreased in LPS-treated rats, while that of ANP and NPR-A did not change. ANP-stimulated GC activity reduced in the glomerulus and papilla. In conclusion, enhancement of the NO/cGMP pathway and decrease in ANP clearance were found play a role in the pathogenesis of LPS-induced kidney injury.

Entities:  

Keywords:  Atrial natriuretic peptide; Guanylyl cyclase; Lipopolysaccharide; Nitric oxide

Year:  2011        PMID: 22128259      PMCID: PMC3222796          DOI: 10.4196/kjpp.2011.15.5.273

Source DB:  PubMed          Journal:  Korean J Physiol Pharmacol        ISSN: 1226-4512            Impact factor:   2.016


  23 in total

Review 1.  Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia.

Authors:  G del Zoppo; I Ginis; J M Hallenbeck; C Iadecola; X Wang; G Z Feuerstein
Journal:  Brain Pathol       Date:  2000-01       Impact factor: 6.508

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 3.  The natriuretic-peptide family.

Authors:  M R Wilkins; J Redondo; L A Brown
Journal:  Lancet       Date:  1997-05-03       Impact factor: 79.321

Review 4.  Nitric oxide and macrophage function.

Authors:  J MacMicking; Q W Xie; C Nathan
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

Review 5.  Pathophysiology and treatment of septic shock.

Authors:  E C Rackow; M E Astiz
Journal:  JAMA       Date:  1991 Jul 24-31       Impact factor: 56.272

6.  Role of nitric oxide in lipopolysaccharide-induced oxidant stress in the rat kidney.

Authors:  C Zhang; L M Walker; P R Mayeux
Journal:  Biochem Pharmacol       Date:  2000-01-15       Impact factor: 5.858

Review 7.  Nitric oxide in septic shock.

Authors:  M A Titheradge
Journal:  Biochim Biophys Acta       Date:  1999-05-05

8.  Lipopolysaccharide alters vasodilation to atrial natriuretic peptide via nitric oxide and endothelin-1: time-dependent effects.

Authors:  Johann K Scicluna; Arnaud Mansart; Jonathan J Ross; Charles S Reilly; Nicola J Brown; Zoë L S Brookes
Journal:  Eur J Pharmacol       Date:  2009-09-06       Impact factor: 4.432

9.  Circulating concentrations and physiologic role of atrial natriuretic peptide during endotoxic shock in the rat.

Authors:  K Aiura; M Ueda; M Endo; M Kitajima
Journal:  Crit Care Med       Date:  1995-11       Impact factor: 7.598

10.  In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia.

Authors:  E Noiri; T Peresleni; F Miller; M S Goligorsky
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

View more
  4 in total

Review 1.  Therapeutic interventions in sepsis: current and anticipated pharmacological agents.

Authors:  Prashant Shukla; G Madhava Rao; Gitu Pandey; Shweta Sharma; Naresh Mittapelly; Ranjita Shegokar; Prabhat Ranjan Mishra
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

2.  Aortic disease in Marfan syndrome is caused by overactivation of sGC-PRKG signaling by NO.

Authors:  Andrea de la Fuente-Alonso; Marta Toral; Alvaro Alfayate; María Jesús Ruiz-Rodríguez; Elena Bonzón-Kulichenko; Gisela Teixido-Tura; Sara Martínez-Martínez; María José Méndez-Olivares; Dolores López-Maderuelo; Ileana González-Valdés; Eusebio Garcia-Izquierdo; Susana Mingo; Carlos E Martín; Laura Muiño-Mosquera; Julie De Backer; J Francisco Nistal; Alberto Forteza; Arturo Evangelista; Jesús Vázquez; Miguel R Campanero; Juan Miguel Redondo
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

3.  Altered regulation of renal Acid base transporters in response to ammonium chloride loading in rats.

Authors:  Eun Young Kim; Joon Seok Choi; Ko Eun Lee; Chang Seong Kim; Eun Hui Bae; Seong Kwon Ma; Suhn Hee Kim; Jong Un Lee; Soo Wan Kim
Journal:  Korean J Physiol Pharmacol       Date:  2012-04-24       Impact factor: 2.016

4.  Urinary cGMP predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus before exposure to contrast medium.

Authors:  Lyubov Chaykovska; Fabian Heunisch; Gina von Einem; Carl-Friedrich Hocher; Oleg Tsuprykov; Mira Pavkovic; Peter Sandner; Axel Kretschmer; Chang Chu; Saban Elitok; Johannes-Peter Stasch; Berthold Hocher
Journal:  PLoS One       Date:  2018-04-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.